**Abstract**

There is an unmet need to improve the diagnosis of treatment-resistant depression (TRD). Current diagnostic metrics fail to accurately identify patients who will not respond to first-line and subsequent therapeutic strategies. However, there is increasing evidence to support the concept of biomarkers as a means to improve diagnostic precision and refine treatment options for TRD. MicroRNAs are small nucleotide sequences that regulate gene expression and accumulating evidence has linked their presence in the periphery to the pathophysiology of depression. Thus, we hypothesised that microRNAs could serve as biomarkers for TRD. We further proposed that baseline microRNA expression could predict remission with ketamine infusions (KET) or electroconvulsive therapy (ECT).

To test these hypotheses, we studied the peripheral microRNA expression profiles of healthy controls (n=17) and patients (n=30) with TRD who received treatment with infusions of KET (0.5mg/kg IV over 40 min) or ECT (average of 8.9 sessions per patient). Remission following treatments was defined as at least a 50% reduction in the Hamilton Depression Rating Scale scores. RNA was isolated from blood samples collected at baseline and after treatments. To determine differences in microRNA expression, microarray (Exiqon) and qPCR analyses were performed on samples.

The baseline expression of let-7b was significantly reduced by 40% in TRD patients. Bioinformatic analysis revealed that let-7b regulates the expression of 25 genes in the PI3k-Akt-mTOR signaling pathway which has previously been reported to be dysfunctional in depression. KET and ECT both had positive effects in attenuating depression symptomatology and 72% of patients achieved remission. However, we found no microRNAs altered by treatment and remission could not be predicted from baseline microRNA expression profiles.

Our data suggests that let-7b is a putative peripheral trait-biomarker for TRD. Experiments are on-going to study the functional effects of let-7b and how they relate to the pathophysiology of depression.
